Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift
Identifieur interne : 001308 ( Istex/Corpus ); précédent : 001307; suivant : 001309Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift
Auteurs : R. Pyh L ; L. Kinnunen ; V. Kumpulainen ; N. Ikonen ; M. Kleemola ; K. CantellSource :
- Vaccine [ 0264-410X ] ; 1993.
English descriptors
- Teeft :
- Amino, Amino acid differences, Amino acids, Antibody, Antibody reactivity, Antibody response, Antibody responses, Antibody titres, Antigenic, Antigenic analysis, Antigenic differences, Antigenic drift, Cell cultures, Clinical material, Conspicuous decreases, Elderly people, Embryonated eggs, Epidemic influenza, Epidemic season, Epidemiol, Field strains, First time, Genembl data base, Haemagglutinin, Higher prevaccination, Human sera, Immune response, Immunological memory, Influenza, Influenza vaccine, Influenza virus, Influenza viruses, Latter viruses, Mammalian virus, Mdck, Mdck cell cultures, Older people, Older subjects, Postepidemic, Postepidemic antibody titres, Postvaccination, Postvaccination protection rates, Postvaccination sera, Present study, Prevaccination, Prevaccination antibody, Prevaccination antibody titres, Protection rate, Protection rates, Reference strains, Response rate, Sequence analysis, Seronegative subjects, Seroneoative subjects, Subtype, Subtype viruses, Successive samples, Titre, Trivalent, Trivalent influenza virus vaccine, Vaccine, Vaccine strain, Vaccine virus, Virol, Virus, Virus antigens, Virus haemagglutinin, Virus strain, Wkly epidemiol, World health organization, Young adults, Younger subjects.
Abstract
Abstract: In Autumn 1990, trivalent split influenza virus vaccine containing A/Taiwan/1/86(H1N1) was used to immunize healthy female employees (n = 104). The 11–12 amino acid differences in the HA1 domain of virus haemagglutinin between A/Taiwan/1/86 and representative epidemic H1N1 strains in Finland in 1991 did not result in lowered haemagglutination-inhibiting (HI) antibody responses to the latter viruses. In fact, higher prevaccination, postvaccination and postepidemic antibody titres were recorded against the new field strains than against the vaccine virus; the highest being against field strains grown exclusively in MDCK cell cultures. This pattern is primarily explained by differences in the sensitivity of the viruses for detecting HI antibodies. Postvaccination protection rates of 98–100% for the MDCK-grown avid viruses were noted in subjects who exhibited prevaccination antibody. Lower protection rates were recorded in initially seronegative subjects, the lowest (54–57%) being among older people, i.e. among vaccinees born in 1930–1955 (p < 0.001). Moreover, conspicuous decreases in protection rates were detected during the following epidemic season in the initially seronegative subjects. Diagnostic findings during outbreaks due to H1N1 subtype viruses also support the impression that many middle-aged people are poorly primed. Thus, vaccination with two doses may be worth considering when such people join the high-risk group and receive influenza vaccine for the first time.
Url:
DOI: 10.1016/0264-410X(93)90126-I
Links to Exploration step
ISTEX:0DC805796487268DDC03FB179046F00CB22081A7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift</title><author><name sortKey="Pyh L, R" sort="Pyh L, R" uniqKey="Pyh L R" first="R." last="Pyh L">R. Pyh L</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Kinnunen, L" sort="Kinnunen, L" uniqKey="Kinnunen L" first="L." last="Kinnunen">L. Kinnunen</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Kumpulainen, V" sort="Kumpulainen, V" uniqKey="Kumpulainen V" first="V." last="Kumpulainen">V. Kumpulainen</name><affiliation><mods:affiliation>Helsinki City Occupational Health Care Unit, Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Ikonen, N" sort="Ikonen, N" uniqKey="Ikonen N" first="N." last="Ikonen">N. Ikonen</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Kleemola, M" sort="Kleemola, M" uniqKey="Kleemola M" first="M." last="Kleemola">M. Kleemola</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Cantell, K" sort="Cantell, K" uniqKey="Cantell K" first="K." last="Cantell">K. Cantell</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0DC805796487268DDC03FB179046F00CB22081A7</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1016/0264-410X(93)90126-I</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-MZ6J8WLB-D/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001308</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001308</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift</title><author><name sortKey="Pyh L, R" sort="Pyh L, R" uniqKey="Pyh L R" first="R." last="Pyh L">R. Pyh L</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Kinnunen, L" sort="Kinnunen, L" uniqKey="Kinnunen L" first="L." last="Kinnunen">L. Kinnunen</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Kumpulainen, V" sort="Kumpulainen, V" uniqKey="Kumpulainen V" first="V." last="Kumpulainen">V. Kumpulainen</name><affiliation><mods:affiliation>Helsinki City Occupational Health Care Unit, Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Ikonen, N" sort="Ikonen, N" uniqKey="Ikonen N" first="N." last="Ikonen">N. Ikonen</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Kleemola, M" sort="Kleemola, M" uniqKey="Kleemola M" first="M." last="Kleemola">M. Kleemola</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author><author><name sortKey="Cantell, K" sort="Cantell, K" uniqKey="Cantell K" first="K." last="Cantell">K. Cantell</name><affiliation><mods:affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993">1993</date><biblScope unit="volume">11</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1013">1013</biblScope><biblScope unit="page" to="1017">1017</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Amino</term><term>Amino acid differences</term><term>Amino acids</term><term>Antibody</term><term>Antibody reactivity</term><term>Antibody response</term><term>Antibody responses</term><term>Antibody titres</term><term>Antigenic</term><term>Antigenic analysis</term><term>Antigenic differences</term><term>Antigenic drift</term><term>Cell cultures</term><term>Clinical material</term><term>Conspicuous decreases</term><term>Elderly people</term><term>Embryonated eggs</term><term>Epidemic influenza</term><term>Epidemic season</term><term>Epidemiol</term><term>Field strains</term><term>First time</term><term>Genembl data base</term><term>Haemagglutinin</term><term>Higher prevaccination</term><term>Human sera</term><term>Immune response</term><term>Immunological memory</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenza virus</term><term>Influenza viruses</term><term>Latter viruses</term><term>Mammalian virus</term><term>Mdck</term><term>Mdck cell cultures</term><term>Older people</term><term>Older subjects</term><term>Postepidemic</term><term>Postepidemic antibody titres</term><term>Postvaccination</term><term>Postvaccination protection rates</term><term>Postvaccination sera</term><term>Present study</term><term>Prevaccination</term><term>Prevaccination antibody</term><term>Prevaccination antibody titres</term><term>Protection rate</term><term>Protection rates</term><term>Reference strains</term><term>Response rate</term><term>Sequence analysis</term><term>Seronegative subjects</term><term>Seroneoative subjects</term><term>Subtype</term><term>Subtype viruses</term><term>Successive samples</term><term>Titre</term><term>Trivalent</term><term>Trivalent influenza virus vaccine</term><term>Vaccine</term><term>Vaccine strain</term><term>Vaccine virus</term><term>Virol</term><term>Virus</term><term>Virus antigens</term><term>Virus haemagglutinin</term><term>Virus strain</term><term>Wkly epidemiol</term><term>World health organization</term><term>Young adults</term><term>Younger subjects</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: In Autumn 1990, trivalent split influenza virus vaccine containing A/Taiwan/1/86(H1N1) was used to immunize healthy female employees (n = 104). The 11–12 amino acid differences in the HA1 domain of virus haemagglutinin between A/Taiwan/1/86 and representative epidemic H1N1 strains in Finland in 1991 did not result in lowered haemagglutination-inhibiting (HI) antibody responses to the latter viruses. In fact, higher prevaccination, postvaccination and postepidemic antibody titres were recorded against the new field strains than against the vaccine virus; the highest being against field strains grown exclusively in MDCK cell cultures. This pattern is primarily explained by differences in the sensitivity of the viruses for detecting HI antibodies. Postvaccination protection rates of 98–100% for the MDCK-grown avid viruses were noted in subjects who exhibited prevaccination antibody. Lower protection rates were recorded in initially seronegative subjects, the lowest (54–57%) being among older people, i.e. among vaccinees born in 1930–1955 (p < 0.001). Moreover, conspicuous decreases in protection rates were detected during the following epidemic season in the initially seronegative subjects. Diagnostic findings during outbreaks due to H1N1 subtype viruses also support the impression that many middle-aged people are poorly primed. Thus, vaccination with two doses may be worth considering when such people join the high-risk group and receive influenza vaccine for the first time.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>antigenic</json:string><json:string>prevaccination</json:string><json:string>vaccine</json:string><json:string>influenza</json:string><json:string>postvaccination</json:string><json:string>virol</json:string><json:string>influenza viruses</json:string><json:string>haemagglutinin</json:string><json:string>mdck</json:string><json:string>older subjects</json:string><json:string>trivalent</json:string><json:string>epidemiol</json:string><json:string>postepidemic</json:string><json:string>field strains</json:string><json:string>protection rates</json:string><json:string>mdck cell cultures</json:string><json:string>present study</json:string><json:string>antigenic analysis</json:string><json:string>titre</json:string><json:string>subtype viruses</json:string><json:string>world health organization</json:string><json:string>virus strain</json:string><json:string>protection rate</json:string><json:string>virus</json:string><json:string>amino</json:string><json:string>response rate</json:string><json:string>amino acid differences</json:string><json:string>influenza vaccine</json:string><json:string>vaccine virus</json:string><json:string>antigenic drift</json:string><json:string>wkly epidemiol</json:string><json:string>prevaccination antibody</json:string><json:string>reference strains</json:string><json:string>postvaccination sera</json:string><json:string>human sera</json:string><json:string>antibody response</json:string><json:string>antibody titres</json:string><json:string>antibody</json:string><json:string>prevaccination antibody titres</json:string><json:string>young adults</json:string><json:string>vaccine strain</json:string><json:string>trivalent influenza virus vaccine</json:string><json:string>first time</json:string><json:string>clinical material</json:string><json:string>successive samples</json:string><json:string>embryonated eggs</json:string><json:string>conspicuous decreases</json:string><json:string>older people</json:string><json:string>seroneoative subjects</json:string><json:string>virus haemagglutinin</json:string><json:string>postvaccination protection rates</json:string><json:string>cell cultures</json:string><json:string>postepidemic antibody titres</json:string><json:string>virus antigens</json:string><json:string>younger subjects</json:string><json:string>elderly people</json:string><json:string>seronegative subjects</json:string><json:string>amino acids</json:string><json:string>genembl data base</json:string><json:string>epidemic season</json:string><json:string>immunological memory</json:string><json:string>antigenic differences</json:string><json:string>higher prevaccination</json:string><json:string>latter viruses</json:string><json:string>immune response</json:string><json:string>antibody reactivity</json:string><json:string>epidemic influenza</json:string><json:string>antibody responses</json:string><json:string>sequence analysis</json:string><json:string>influenza virus</json:string><json:string>mammalian virus</json:string><json:string>subtype</json:string></teeft></keywords><author><json:item><name>R. Pyhälä</name><affiliations><json:string>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</json:string></affiliations></json:item><json:item><name>L. Kinnunen</name><affiliations><json:string>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</json:string></affiliations></json:item><json:item><name>V. Kumpulainen</name><affiliations><json:string>Helsinki City Occupational Health Care Unit, Helsinki, Finland</json:string></affiliations></json:item><json:item><name>N. Ikonen</name><affiliations><json:string>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</json:string></affiliations></json:item><json:item><name>M. Kleemola</name><affiliations><json:string>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</json:string></affiliations></json:item><json:item><name>K. Cantell</name><affiliations><json:string>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Influenza A(H1N1)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>haemagglutinin gene</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HI antibodies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>serological match</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MDCK-grown virus</value></json:item></subject><arkIstex>ark:/67375/6H6-MZ6J8WLB-D</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: In Autumn 1990, trivalent split influenza virus vaccine containing A/Taiwan/1/86(H1N1) was used to immunize healthy female employees (n = 104). The 11–12 amino acid differences in the HA1 domain of virus haemagglutinin between A/Taiwan/1/86 and representative epidemic H1N1 strains in Finland in 1991 did not result in lowered haemagglutination-inhibiting (HI) antibody responses to the latter viruses. In fact, higher prevaccination, postvaccination and postepidemic antibody titres were recorded against the new field strains than against the vaccine virus; the highest being against field strains grown exclusively in MDCK cell cultures. This pattern is primarily explained by differences in the sensitivity of the viruses for detecting HI antibodies. Postvaccination protection rates of 98–100% for the MDCK-grown avid viruses were noted in subjects who exhibited prevaccination antibody. Lower protection rates were recorded in initially seronegative subjects, the lowest (54–57%) being among older people, i.e. among vaccinees born in 1930–1955 (p > 0.001). Moreover, conspicuous decreases in protection rates were detected during the following epidemic season in the initially seronegative subjects. Diagnostic findings during outbreaks due to H1N1 subtype viruses also support the impression that many middle-aged people are poorly primed. Thus, vaccination with two doses may be worth considering when such people join the high-risk group and receive influenza vaccine for the first time.</abstract><qualityIndicators><score>7.878</score><pdfWordCount>3334</pdfWordCount><pdfCharCount>21621</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>584 x 836 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>212</abstractWordCount><abstractCharCount>1507</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift</title><pmid><json:string>8212820</json:string></pmid><pii><json:string>0264-410X(93)90126-I</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Prevalence of antibody to current influenza virus strains in a 1991 Canadian serosurvey</title><language><json:string>unknown</json:string></language><pages><first>205</first></pages></serie><host><title>Vaccine</title><language><json:string>unknown</json:string></language><publicationDate>1993</publicationDate><issn><json:string>0264-410X</json:string></issn><pii><json:string>S0264-410X(00)X0192-2</json:string></pii><volume>11</volume><issue>10</issue><pages><first>1013</first><last>1017</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2s</json:string><json:string>1930</json:string><json:string>1957</json:string><json:string>1986</json:string><json:string>1993</json:string><json:string>1990</json:string><json:string>1977</json:string><json:string>1991</json:string><json:string>1956</json:string></date><geogName></geogName><orgName><json:string>US Department of Health and Human Services</json:string><json:string>National Public Health Institute, Mannerheimintie</json:string><json:string>Connaught Laboratories</json:string><json:string>World Health Organization</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Y. Vaccination</json:string><json:string>Isabella Donatelli</json:string><json:string>J. Virol</json:string><json:string>J. Epidemiol</json:string><json:string>Procedures</json:string><json:string>J. EpidemioL</json:string><json:string>K. Cantell</json:string><json:string>J.S. Antigenic</json:string><json:string>J. Skehel</json:string><json:string>A. Surveillance</json:string><json:string>J. Gen</json:string><json:string>J. Med</json:string><json:string>R.G. Jr</json:string><json:string>R. Pyh</json:string><json:string>J. Aust</json:string><json:string>J.C. de Jong</json:string><json:string>J.J. Concepts</json:string><json:string>R. Evolution</json:string><json:string>Viral Vaccines</json:string><json:string>R.G. Evidence</json:string><json:string>J. Clin</json:string><json:string>G.V. Jr</json:string><json:string>J.M. Influenza</json:string><json:string>I.T. Sequence</json:string><json:string>A.P. Pathways</json:string></persName><placeName><json:string>Singapore</json:string><json:string>Finland</json:string><json:string>Brazil</json:string><json:string>Taiwan</json:string><json:string>Helsinki</json:string><json:string>Immunogenicity</json:string><json:string>Italy</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Autumn 1990</json:string><json:string>May 1991</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-MZ6J8WLB-D</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Public Health, Environmental and Occupational Health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - General Immunology and Microbiology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - pathologie infectieuse</json:string></inist></categories><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1016/0264-410X(93)90126-I</json:string></doi><id>0DC805796487268DDC03FB179046F00CB22081A7</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MZ6J8WLB-D/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MZ6J8WLB-D/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-MZ6J8WLB-D/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1993</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift</title><author xml:id="author-0000"><persName><forename type="first">R.</forename><surname>Pyhälä</surname></persName><affiliation>To whom correspondence should be addressed.</affiliation><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation></author><author xml:id="author-0001"><persName><forename type="first">L.</forename><surname>Kinnunen</surname></persName><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation></author><author xml:id="author-0002"><persName><forename type="first">V.</forename><surname>Kumpulainen</surname></persName><affiliation>Helsinki City Occupational Health Care Unit, Helsinki, Finland</affiliation></author><author xml:id="author-0003"><persName><forename type="first">N.</forename><surname>Ikonen</surname></persName><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation></author><author xml:id="author-0004"><persName><forename type="first">M.</forename><surname>Kleemola</surname></persName><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation></author><author xml:id="author-0005"><persName><forename type="first">K.</forename><surname>Cantell</surname></persName><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation></author><idno type="istex">0DC805796487268DDC03FB179046F00CB22081A7</idno><idno type="ark">ark:/67375/6H6-MZ6J8WLB-D</idno><idno type="DOI">10.1016/0264-410X(93)90126-I</idno><idno type="PII">0264-410X(93)90126-I</idno></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0192-2</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993"></date><biblScope unit="volume">11</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1013">1013</biblScope><biblScope unit="page" to="1017">1017</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: In Autumn 1990, trivalent split influenza virus vaccine containing A/Taiwan/1/86(H1N1) was used to immunize healthy female employees (n = 104). The 11–12 amino acid differences in the HA1 domain of virus haemagglutinin between A/Taiwan/1/86 and representative epidemic H1N1 strains in Finland in 1991 did not result in lowered haemagglutination-inhibiting (HI) antibody responses to the latter viruses. In fact, higher prevaccination, postvaccination and postepidemic antibody titres were recorded against the new field strains than against the vaccine virus; the highest being against field strains grown exclusively in MDCK cell cultures. This pattern is primarily explained by differences in the sensitivity of the viruses for detecting HI antibodies. Postvaccination protection rates of 98–100% for the MDCK-grown avid viruses were noted in subjects who exhibited prevaccination antibody. Lower protection rates were recorded in initially seronegative subjects, the lowest (54–57%) being among older people, i.e. among vaccinees born in 1930–1955 (p < 0.001). Moreover, conspicuous decreases in protection rates were detected during the following epidemic season in the initially seronegative subjects. Diagnostic findings during outbreaks due to H1N1 subtype viruses also support the impression that many middle-aged people are poorly primed. Thus, vaccination with two doses may be worth considering when such people join the high-risk group and receive influenza vaccine for the first time.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Influenza A(H1N1)</term></item><item><term>haemagglutinin gene</term></item><item><term>HI antibodies</term></item><item><term>serological match</term></item><item><term>MDCK-grown virus</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1992-08-10">Modified</change><change when="1993">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MZ6J8WLB-D/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JVAC</jid><aid>9390126I</aid><ce:pii>0264-410X(93)90126-I</ce:pii><ce:doi>10.1016/0264-410X(93)90126-I</ce:doi><ce:copyright type="unknown" year="1993"></ce:copyright></item-info><head><ce:title>Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift</ce:title><ce:author-group><ce:author><ce:given-name>R.</ce:given-name><ce:surname>Pyhälä</ce:surname><ce:cross-ref refid="COR1"><ce:sup>‡</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>L.</ce:given-name><ce:surname>Kinnunen</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>V.</ce:given-name><ce:surname>Kumpulainen</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>N.</ce:given-name><ce:surname>Ikonen</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>M.</ce:given-name><ce:surname>Kleemola</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>K.</ce:given-name><ce:surname>Cantell</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>∗</ce:label><ce:textfn>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>†</ce:label><ce:textfn>Helsinki City Occupational Health Care Unit, Helsinki, Finland</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>‡</ce:label><ce:text>To whom correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="4" month="5" year="1992"></ce:date-received><ce:date-revised day="10" month="8" year="1992"></ce:date-revised><ce:date-accepted day="25" month="9" year="1992"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>In Autumn 1990, trivalent split influenza virus vaccine containing A/Taiwan/1/86(H1N1) was used to immunize healthy female employees (<ce:italic>n</ce:italic> = 104). The 11–12 amino acid differences in the HA1 domain of virus haemagglutinin between A/Taiwan/1/86 and representative epidemic H1N1 strains in Finland in 1991 did not result in lowered haemagglutination-inhibiting (HI) antibody responses to the latter viruses. In fact, higher prevaccination, postvaccination and postepidemic antibody titres were recorded against the new field strains than against the vaccine virus; the highest being against field strains grown exclusively in MDCK cell cultures. This pattern is primarily explained by differences in the sensitivity of the viruses for detecting HI antibodies. Postvaccination protection rates of 98–100% for the MDCK-grown avid viruses were noted in subjects who exhibited prevaccination antibody. Lower protection rates were recorded in initially seronegative subjects, the lowest (54–57%) being among older people, i.e. among vaccinees born in 1930–1955 (<ce:italic>p</ce:italic> < 0.001). Moreover, conspicuous decreases in protection rates were detected during the following epidemic season in the initially seronegative subjects. Diagnostic findings during outbreaks due to H1N1 subtype viruses also support the impression that many middle-aged people are poorly primed. Thus, vaccination with two doses may be worth considering when such people join the high-risk group and receive influenza vaccine for the first time.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Influenza A(H1N1)</ce:text></ce:keyword><ce:keyword><ce:text>haemagglutinin gene</ce:text></ce:keyword><ce:keyword><ce:text>HI antibodies</ce:text></ce:keyword><ce:keyword><ce:text>serological match</ce:text></ce:keyword><ce:keyword><ce:text>MDCK-grown virus</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift</title></titleInfo><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Pyhälä</namePart><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation><description>To whom correspondence should be addressed.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Kinnunen</namePart><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Kumpulainen</namePart><affiliation>Helsinki City Occupational Health Care Unit, Helsinki, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Ikonen</namePart><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Kleemola</namePart><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Cantell</namePart><affiliation>National Public Health Institute, Mannerheimintie 166, 00300 Helsinki, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued><dateModified encoding="w3cdtf">1992-08-10</dateModified><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: In Autumn 1990, trivalent split influenza virus vaccine containing A/Taiwan/1/86(H1N1) was used to immunize healthy female employees (n = 104). The 11–12 amino acid differences in the HA1 domain of virus haemagglutinin between A/Taiwan/1/86 and representative epidemic H1N1 strains in Finland in 1991 did not result in lowered haemagglutination-inhibiting (HI) antibody responses to the latter viruses. In fact, higher prevaccination, postvaccination and postepidemic antibody titres were recorded against the new field strains than against the vaccine virus; the highest being against field strains grown exclusively in MDCK cell cultures. This pattern is primarily explained by differences in the sensitivity of the viruses for detecting HI antibodies. Postvaccination protection rates of 98–100% for the MDCK-grown avid viruses were noted in subjects who exhibited prevaccination antibody. Lower protection rates were recorded in initially seronegative subjects, the lowest (54–57%) being among older people, i.e. among vaccinees born in 1930–1955 (p < 0.001). Moreover, conspicuous decreases in protection rates were detected during the following epidemic season in the initially seronegative subjects. Diagnostic findings during outbreaks due to H1N1 subtype viruses also support the impression that many middle-aged people are poorly primed. Thus, vaccination with two doses may be worth considering when such people join the high-risk group and receive influenza vaccine for the first time.</abstract><subject><genre>Keywords</genre><topic>Influenza A(H1N1)</topic><topic>haemagglutinin gene</topic><topic>HI antibodies</topic><topic>serological match</topic><topic>MDCK-grown virus</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0192-2</identifier><part><date>1993</date><detail type="volume"><number>11</number><caption>vol.</caption></detail><detail type="issue"><number>10</number><caption>no.</caption></detail><extent unit="issue-pages"><start>987</start><end>1080</end></extent><extent unit="pages"><start>1013</start><end>1017</end></extent></part></relatedItem><identifier type="istex">0DC805796487268DDC03FB179046F00CB22081A7</identifier><identifier type="ark">ark:/67375/6H6-MZ6J8WLB-D</identifier><identifier type="DOI">10.1016/0264-410X(93)90126-I</identifier><identifier type="PII">0264-410X(93)90126-I</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MZ6J8WLB-D/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001308 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001308 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0DC805796487268DDC03FB179046F00CB22081A7
|texte= Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift
}}
| This area was generated with Dilib version V0.6.33. |  |